Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074961 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2GRM8GRM4TSHRSLC7A5 | |
| SCHEMBL7425388 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2GRM8GRM4TSHRSLC7A5 | |
| SCHEMBL4005849 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRCSNK2A1 | |
| SCHEMBL15328477 | 0.77 | SLC7A5 (0.60) | SMN1; SMN2TSHRSLC7A5HSD17B10CYP3A4 | |
| SCHEMBL15328481 | 0.77 | SLC7A5 (0.60) | SMN1; SMN2TSHRSLC7A5HSD17B10CYP3A4 | |
| SCHEMBL9172559 | 0.74 | SLC7A5 (0.55) | TSHRSLC7A5HSD17B10CYP3A4PKM | |
| Bromide SCHEMBL5048845 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2TSHRHSD17B10CSNK2A1EPHX2 | |
| SCHEMBL5835893 | 0.72 | ALDH1A1 (0.46) | SMN1; SMN2TSHRHSD17B10CSNK2A1EPHX2 | |
| SCHEMBL5653620 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2TSHRHSD17B10CSNK2A1EPHX2 | |
| SCHEMBL14780592 | 0.71 | HSD17B10 (0.49) | TSHRSLC7A5HSD17B10CYP3A4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | claimed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-2229138-B1 | TOPICAL COMPOSITIONS COMPRISING NON-PROTEOGENIC AMINO ACIDS AND METHODS OF TREATING SKIN | AVON PROD INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9586988-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-8557781-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8399614-B2 | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides | AMBRX, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8168212-B2 | Topical compositions comprising non-proteogenic amino acids and methods of treating skin | AVON PRODUCTS, INC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | AVON PRODUCTS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | LOXL1, LOXL2, LOXL3 | SMN1; SMN2 2608/4885GRM8 4417/4885GRM4 4727/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | SMN1; SMN2 4155/4885GRM8 2739/4885GRM4 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.